Deborah Koltai Attix
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Deborah Koltai Attix has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
Michael M. Haglund
Duke Global Neurosurgery and Neurology, Duke University, Durham, NC, USA; Department of Neurosurgery, Duke University, Durham, NC, USA; Duke Global Health Institute, Duke University, Durham, NC, USA
11 shared publicationsMartin N. Kaddumukasa
Department of Medicine, Mulago National Referral Hospital, Neurology Unit, Kampala, Uganda
10 shared publicationsMark Kaddumukasa
School of Medicine, College of Health Sciences, Makerere University, P.O. Box 7072, Kampala, Uganda
9 shared publicationsAngelina Kakooza-Mwesige
Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Mulago Hill Road, P.O.Box 7072, Kampala, Uganda; Department of Paediatrics and Child Health, Mulago National Referral Hospital, Pediatric Neurology Unit, Kampala, Uganda
8 shared publicationsAnthony T. Fuller
Duke Division of Global Neurosurgery and Neurology, Department of Neurosurgery, Box 3807, Duke University Medical Center, Durham, NC 27705, USA; Duke Global Health Institute, 310 Trent Dr, Durham, NC 27710, USA; Duke University, School of Medicine, 3100 Tower Blvd, Durham, NC 27707, USA
8 shared publicationsNoeline Nakasujja
Department of Psychiatry, Makerere University College of Health Sciences, P.O. Box 7072, Kampala, Uganda
8 shared publications
Latest Publications
- 26 October 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 186
Pilot testing an epilepsy self-management and resilience smartphone application for adolescents and young adults in Uganda
- 26 October 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 186
Pilot testing an epilepsy self-management and resilience smartphone application for adolescents and young adults in Uganda
- Open Access
- 4 July 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 183, 111167
Explanatory models of epilepsy: key deterrents to seeking biomedical care and effective epilepsy management in Uganda
- 4 July 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 183, 111167
Open AccessExplanatory models of epilepsy: key deterrents to seeking biomedical care and effective epilepsy management in Uganda
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200617
Evaluating the Duke Iterative Cognitive Examination Against the Montreal Cognitive Assessment
Rapid and valid cognitive screening tools are a mainstay of clinical practice in the assessment of mild cognitive impairment and dementia. Although there are several available tools, there is concern for reduced sensitivity over time. This study evaluates the Duke Iterative Cognitive Examination (DICE) to establish concurrent validity with the Montreal Cognitive Assessment (MoCA) and to establish the clinical utility of the DICE in differentiating clinical groups. Participants were enrolled prospectively and included a convenience sample of 126 healthy older adults, 59 individuals with mild cognitive impairment (MCI), and 66 with dementia, all age 55+. All participants were administered the MoCA and the DICE in counterbalanced order. Spearman rank-order correlation examined the relationship between DICE and MoCA scores. Likelihood ratio (L-R) chi-square tests assessed the predictive value of cognitive scores, age, sex, and education in diagnostic classification. Receiver operating characteristic curve analyses evaluated classification accuracy for both tests. The correlation between the DICE and MoCA was strong, suggesting concurrent validity (ρ = 0.89, p < 0.001). Both measures significantly predicted diagnostic groups and demonstrated strong classification accuracy (MoCA AUC = 0.97 (controls), 0.85 (MCI), 0.95 (dementia); DICE AUC = 0.97, 0.94, 0.83, respectively). The DICE performed comparably to the MoCA in the current sample of older healthy adults and clinical groups with MCI and dementia. Findings suggest that the DICE is a reasonable and valid screening measure, and future studies should examine other psychometric aspects of the test, such as test-retest reliability, latent factor structure, and longitudinal clinical prediction.
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200617
Evaluating the Duke Iterative Cognitive Examination Against the Montreal Cognitive Assessment
Rapid and valid cognitive screening tools are a mainstay of clinical practice in the assessment of mild cognitive impairment and dementia. Although there are several available tools, there is concern for reduced sensitivity over time. This study evaluates the Duke Iterative Cognitive Examination (DICE) to establish concurrent validity with the Montreal Cognitive Assessment (MoCA) and to establish the clinical utility of the DICE in differentiating clinical groups. Participants were enrolled prospectively and included a convenience sample of 126 healthy older adults, 59 individuals with mild cognitive impairment (MCI), and 66 with dementia, all age 55+. All participants were administered the MoCA and the DICE in counterbalanced order. Spearman rank-order correlation examined the relationship between DICE and MoCA scores. Likelihood ratio (L-R) chi-square tests assessed the predictive value of cognitive scores, age, sex, and education in diagnostic classification. Receiver operating characteristic curve analyses evaluated classification accuracy for both tests. The correlation between the DICE and MoCA was strong, suggesting concurrent validity (ρ = 0.89, p < 0.001). Both measures significantly predicted diagnostic groups and demonstrated strong classification accuracy (MoCA AUC = 0.97 (controls), 0.85 (MCI), 0.95 (dementia); DICE AUC = 0.97, 0.94, 0.83, respectively). The DICE performed comparably to the MoCA in the current sample of older healthy adults and clinical groups with MCI and dementia. Findings suggest that the DICE is a reasonable and valid screening measure, and future studies should examine other psychometric aspects of the test, such as test-retest reliability, latent factor structure, and longitudinal clinical prediction.
- Open Access
- 8 April 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 180, 111021
Community perspectives and recommendations to reduce epilepsy stigma and enhance effective management of epilepsy in Uganda: A qualitative study
- 8 April 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 180, 111021
Open AccessCommunity perspectives and recommendations to reduce epilepsy stigma and enhance effective management of epilepsy in Uganda: A qualitative study
Population‐based prevalence of epilepsy in Uganda: A nationwide cross‐sectional survey
Objective: Establishing the prevalence of epilepsy in Uganda is crucial to inform interventions and public policy. We conducted a nationwide survey to determine epilepsy prevalence. Methods: From January 2019 to July 2022, a door‐to‐door survey was conducted across all four regions of Uganda, targeting a nationally representative sample of households. Trained field teams identified and interviewed heads of households to obtain demographic information, and three household members were randomly selected for epilepsy screening. A two‐part survey, adapted from a validated standardized epilepsy questionnaire in low‐ and middle‐income countries, was used for screening. To ensure the accuracy of the prevalence estimates, a subset of screened individuals underwent clinical validation by a qualified neurologist. Epilepsy was defined per the International League Against Epilepsy (ILAE) criteria. We employed Monte Carlo simulation to extrapolate prevalence estimates. Results: We identified and screened 35 055 participants (53.5% female). The ages ranged from 1 month to 108 years, with a mean age of 20.7 years. The overall crude epilepsy prevalence was estimated at 16.9 per 1000 persons, with an age‐ and sex‐adjusted prevalence rate of 17.8 per 1000. The differences in sex‐specific prevalence rates were not statistically significant. The highest age‐specific prevalence rate of 25.0 per 1000 occurred in the 20‐ to 39 ‐year age group. There was a substantial variation in epilepsy prevalence across the various regions, with the highest prevalence recorded in the eastern region and the lowest in the northern region. Significance: Our study underscores the high epilepsy burden in Uganda, particularly among adults, and reveals age, gender, and geographical variation likely arising from disparities in the underlying determinants. Identification of these factors is crucial for addressing treatment gaps and reducing epilepsy prevalence.
Population‐based prevalence of epilepsy in Uganda: A nationwide cross‐sectional survey
Objective: Establishing the prevalence of epilepsy in Uganda is crucial to inform interventions and public policy. We conducted a nationwide survey to determine epilepsy prevalence. Methods: From January 2019 to July 2022, a door‐to‐door survey was conducted across all four regions of Uganda, targeting a nationally representative sample of households. Trained field teams identified and interviewed heads of households to obtain demographic information, and three household members were randomly selected for epilepsy screening. A two‐part survey, adapted from a validated standardized epilepsy questionnaire in low‐ and middle‐income countries, was used for screening. To ensure the accuracy of the prevalence estimates, a subset of screened individuals underwent clinical validation by a qualified neurologist. Epilepsy was defined per the International League Against Epilepsy (ILAE) criteria. We employed Monte Carlo simulation to extrapolate prevalence estimates. Results: We identified and screened 35 055 participants (53.5% female). The ages ranged from 1 month to 108 years, with a mean age of 20.7 years. The overall crude epilepsy prevalence was estimated at 16.9 per 1000 persons, with an age‐ and sex‐adjusted prevalence rate of 17.8 per 1000. The differences in sex‐specific prevalence rates were not statistically significant. The highest age‐specific prevalence rate of 25.0 per 1000 occurred in the 20‐ to 39 ‐year age group. There was a substantial variation in epilepsy prevalence across the various regions, with the highest prevalence recorded in the eastern region and the lowest in the northern region. Significance: Our study underscores the high epilepsy burden in Uganda, particularly among adults, and reveals age, gender, and geographical variation likely arising from disparities in the underlying determinants. Identification of these factors is crucial for addressing treatment gaps and reducing epilepsy prevalence.
- 1 July 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (7) , 1722-1729
MRI Predictors of Cognitive Function After Lacunar Infarction
BACKGROUND: Poststroke cognitive impairment is associated with disability and decreased quality of life. We assessed whether individual or collective magnetic resonance imaging (MRI) biomarkers can aid in predicting cognitive impairment after lacunar infarction (LACI). METHODS: We conducted a retrospective analysis of data from the American Stroke Association Bugher Small Vessel Study, which included 134 patients within 2 years of an acute LACI, enrolled between 2007 and 2012 at 4 North Carolina hospitals. MRI brain measures at the time of the stroke included as follows: 1, total number of LACIs (index LACI and nonindex radiographic lacunes); 2, size of the largest lacune; 3, ventricular size; 4, cerebral atrophy; 5, radiographic locations (supratentorial, infratentorial, or both); and 6, white matter disease (WMD) extent. WMD extent, cerebral atrophy, and ventricular size were graded using the CHS (Cardiovascular Health Study) scores. The primary outcomes were as follows: 1, total score on Short-Form Montreal Cognitive Assessment to assess global cognition; and 2, time to complete TRAIL Making Test Part B (TMT-B) to evaluate executive function. Regression analyses were used to assess the association between the 6 MRI measures and cognitive function adjusting for demographic and clinical variables. RESULTS: One hundred thirty-four participants completed Short-Form Montreal Cognitive Assessment testing and 100 completed TMT-B at a mean of 76.5 (SD, 172.7) days from the index LACI. There were no associations between MRI characteristics and Short-Form Montreal Cognitive Assessment. On univariable analyses, cerebral atrophy (β=35 [95% CI, 14.17–55.83]; P =0.0010), ventricular size (β=40.1 [95% CI, 22.24–57.96]; P P P <0.0001). In adjusted models after performing variable selection, the extent of WMD remained the only MRI measure associated with TMT-B time. CONCLUSIONS: Among the assessed MRI measures, only the extent of WMD was independently associated with executive function after LACI.
- 1 July 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (7) , 1722-1729
MRI Predictors of Cognitive Function After Lacunar Infarction
BACKGROUND: Poststroke cognitive impairment is associated with disability and decreased quality of life. We assessed whether individual or collective magnetic resonance imaging (MRI) biomarkers can aid in predicting cognitive impairment after lacunar infarction (LACI). METHODS: We conducted a retrospective analysis of data from the American Stroke Association Bugher Small Vessel Study, which included 134 patients within 2 years of an acute LACI, enrolled between 2007 and 2012 at 4 North Carolina hospitals. MRI brain measures at the time of the stroke included as follows: 1, total number of LACIs (index LACI and nonindex radiographic lacunes); 2, size of the largest lacune; 3, ventricular size; 4, cerebral atrophy; 5, radiographic locations (supratentorial, infratentorial, or both); and 6, white matter disease (WMD) extent. WMD extent, cerebral atrophy, and ventricular size were graded using the CHS (Cardiovascular Health Study) scores. The primary outcomes were as follows: 1, total score on Short-Form Montreal Cognitive Assessment to assess global cognition; and 2, time to complete TRAIL Making Test Part B (TMT-B) to evaluate executive function. Regression analyses were used to assess the association between the 6 MRI measures and cognitive function adjusting for demographic and clinical variables. RESULTS: One hundred thirty-four participants completed Short-Form Montreal Cognitive Assessment testing and 100 completed TMT-B at a mean of 76.5 (SD, 172.7) days from the index LACI. There were no associations between MRI characteristics and Short-Form Montreal Cognitive Assessment. On univariable analyses, cerebral atrophy (β=35 [95% CI, 14.17–55.83]; P =0.0010), ventricular size (β=40.1 [95% CI, 22.24–57.96]; P P P <0.0001). In adjusted models after performing variable selection, the extent of WMD remained the only MRI measure associated with TMT-B time. CONCLUSIONS: Among the assessed MRI measures, only the extent of WMD was independently associated with executive function after LACI.
- 6 September 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 147, 109402
Epilepsy among the older population of sub-Saharan Africa: Analysis of the global burden of disease database
- 6 September 2023
- Published by Elsevier in Epilepsy & Behavior
- Vol. 147, 109402
Epilepsy among the older population of sub-Saharan Africa: Analysis of the global burden of disease database
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114 (Pt B) , 107349
Barriers to biomedical care for people with epilepsy in Uganda: A cross-sectional study
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114 (Pt B) , 107349
Barriers to biomedical care for people with epilepsy in Uganda: A cross-sectional study
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114 (Pt B) , 107293
Understanding the cultural context of epilepsy care in Uganda: Introduction to this special issue
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114 (Pt B) , 107293
Understanding the cultural context of epilepsy care in Uganda: Introduction to this special issue
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114 (Pt B) , 107381
Stigma reduction interventions for epilepsy: A systematized literature review
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114 (Pt B) , 107381
Stigma reduction interventions for epilepsy: A systematized literature review